NEW
YORK, July 26, 2023 /PRNewswire/ -- Fresh2 Group
Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES)
("Fresh2," the "Company" or "we"), a company with operations in
the United States and China focused on the business-to-business
e-commerce and supply chain sectors for the restaurant supply and
food industry and on early cancer screening and detection,
today announced the appointment of Mr. Yidong Hu as its Chief Strategy Officer (CSO)
effective on July 21, 2023. Mr. Hu
was appointed to drive the advancement and execution of the
Company's long-term strategy.
Mr. Hu is a seasoned executive with over a decade of experience
in the media and finance sectors. Mr.Hu has served as the
Chairman of the Board and the Chief Executive
Officer of Shenzhen Yinhetong Technology Co., Ltd. and SMI
Holdings Group Limited, an investment holding company that operates
theaters in China and was
previously listed on the Hong Kong Exchange. Mr. Hu obtained an
EMBA degree from Graduate School of Tsinghua University and a
bachelor's degree in English from Linyi University in Shandong, China.
"We are delighted to welcome Mr. Yidong
Hu to our team. His expertise and industry insights will
undoubtedly bolster our capabilities and help spearhead strategic
future acquisitions and further enhance Fresh2's growth trajectory
in the dynamic foodservice landscape," said Mr. Haohan Xu, the CEO of Fresh2 Group Ltd.
In response to his appointment, Mr. Hu noted, "Fresh2's
innovative and forward-thinking approach in the food service and
restaurant supply industry is truly commendable. I look forward to
collaborating with the team to further explore technological
advancements, drive industry transformation and create significant
value for all stakeholders."
About Fresh2 Group Limited
Fresh2 Group Limited is engaged in the business-to-business
e-commerce and supply chain sectors. Committed to helping
restaurants lower procurement costs and improve efficiency, Fresh2
utilizes an advanced supply chain management system. By applying
strategic digital technologies and innovative business models,
Fresh2 is driving the online transformation of the restaurant
supply industry. Fresh2 aims to refine restaurant operations,
adding significant value to the food industry, and building a
global network of restaurateurs in the digital age. The
Company is also focused on early cancer screening and detection,
and performs a suite of cancer screening and detection tests,
including CDA (Cancer Differentiation Analysis), bio-chemical,
immunological, and genomics tests. For more information, please
visit: https://fresh2.co/investors.
For investor and media inquiries, please contact:
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-917-609-0333 (U.S.)
Email: tina.xiao@ascent-ir.com
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements are made under the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995
and are relating to the Company's future financial and operating
performance. The Company has attempted to identify forward-looking
statements by terminologies including "believes," "estimates,"
"anticipates," "expects," "plans," "projects," "intends,"
"potential," "target," "aim," "predict," "outlook," "seek," "goal"
"objective," "assume," "contemplate," "continue," "positioned,"
"forecast," "likely," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are based on current expectations, assumptions and
uncertainties involving judgments about, among other things, future
economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the Company's control.
These statements also involve known and unknown risks,
uncertainties and other factors that may cause the Company's actual
results to be materially different from those expressed or implied
by any forward-looking statement. Known and unknown risks,
uncertainties and other factors include, but are not limited to,
our ability to comply with Nasdaq Listing Rules including
maintaining our listing on the Nasdaq Capital Market, the
implementation of our business model and growth strategies; trends
and competition in the cancer screening and detection market; our
expectations regarding demand for and market acceptance of our
cancer screening and detection tests and our ability to expand our
customer base; our ability to obtain and maintain intellectual
property protections for our CDA technology and our continued
research and development to keep pace with technology developments;
our ability to obtain and maintain regulatory approvals from the
NMPA, the FDA and the relevant U.S. states and have our
laboratories certified or accredited by authorities including the
CLIA; our future business development, financial condition and
results of operations and our ability to obtain financing
cost-effectively; potential changes of government regulations;
general economic and business conditions in China and elsewhere; our ability to hire and
maintain key personnel; our relationship with our major business
partners and customers; and the duration of the coronavirus
outbreaks and their potential adverse impact on the economic
conditions and financial markets and our business and financial
performance, such as resulting from reduced commercial activities
due to quarantines and travel restrictions instituted by
China, the U.S. and many other
countries around the world to contain the spread of the virus. A
number of these risks along with additional discussion of
forward-looking statements, are set forth in the Company's Annual
Report on Form 20-F and other reports filed with the Securities and
Exchange Commission. In addition, there is uncertainty about the
spread of the COVID19 virus and the impact it will have on the
Company's operations, global supply chains and economic activity in
general. Because of these and other risks, uncertainties and
assumptions, undue reliance should not be placed on these
forward-looking statements. In addition, these statements speak
only as of the date of this press release and, except as may be
required by law, the Company undertakes no obligation to revise or
update publicly any forward-looking statements for any reason.
View original
content:https://www.prnewswire.com/news-releases/fresh2-group-ltd-appoints-new-chief-strategy-officer-to-drive-advancement-and-execution-of-long-term-growth-strategy-301885709.html
SOURCE Fresh2 Group Limited